LRLiana Valentinovna Ryabova

Liana Valentinovna Ryabova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Liana Valentinovna Ryabova has a total of 55 co-authors. Here are the top co-authors by number of shared publications:

  • Kseniya S. Savchuk

    Saint Petersburg Pasteur Institute

    7 shared publications
  • Eleonora A. Safronova

    South Ural State Medical University; Medical and Biological University of Innovation and Continuous Education, A. Burnazyan Federal Medical Biophysical Center

    6 shared publications
  • Aleksandr Vladimirovich Zurochka

    Institute of Immunology and Physiology of the Ural Branch of the Russian Academy of Sciences; South Ural State University (National Research University)

    5 shared publications
  • Alexey Sarapultsev

    Russian-Chinese Education and Research Center of System Pathology, South Ural State University, Chelyabinsk, Russia

    3 shared publications
  • Eleonora A. Safronova

    South Ural State Medical University

    3 shared publications
  • Зурочка А. В.

    ФГБУН «Институт иммунологии и физиологии» Уральского отделения Российской академии наук; ФБУН «Федеральный научно-исследовательский институт вирусных инфекций “Виром”» Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека

    3 shared publications

Latest Publications

  • Open Access

    Impaired immune response in persons with acute coronary syndrome over post-COVID period, and without a history of COVID-19, depending on the level of CD3+CD8+T cells

    by Сафронова Э. А., E. A. Safronova, L. V. Ryabova, Рябова Л. В., Зурочка А. В., A. V. Zurochka, M. A. Dobrynina, Добрынина М. А., Праскурничий Е. А., E. A. Praskurnichy

    The aim of our study was to evaluate T cell immunity (levels of CD3+CD8+T lymphocytes) in patients with acute coronary syndrome (ACS), with or without history of COVID-19. The study included 85 men with ACS (65 with post-COVID syndrome (PCS) and 20, without it). Lymphocyte profiles were assessed by flow cytometry with a Navios cytofluorimeter (BeckmanCoulter, USA). The blood cell analysis was performed with a Medonic M20 device. The grouping of patients was carried out with respect to presence of PSC, and levels of CD3+CD8+T lymphocytes. Individuals with PCS and high CD3+CD8+T lymphocytes did not have unstable angina, only acute myocardial infarction (AMI) was registered. Meanwhile, the mentioned ACS patients with normal and low CD3+ D8+T lymphocyte counts had a mortality rate of 11.11% and 8.69%, respectively. Thrombosis of drug-eluting stents implanted into coronary vessels was detected in 13.04% and 8.69%, respectively. Post-COVID ACS patients with reduced CD3+CD8+T cell counts demonstrated more pronounced shifts in T cell immunity, i.e., decreased levels of total lymphocytes and T cells, T helpers, early- and late-activation T lymphocytes, and T regulatory cells as well as higher troponin and atherogenic index levels. Thrombosis of the implanted stents occurred in 8.69% of cases, with similar mortality rates. Patients with PCC and normal CD3+CD8+T lymphocyte levels had the highest mortality and stent thrombosis rates. All patients with elevated CD3+CD8+T lymphocyte counts in the post-COVID period experienced acute myocardial infarction with longer hospitalization terms, and higher numbers of coronary stenting. This group of patients showed significantly increased counts of natural killer cells, NKT cells, T helper cells, total T lymphocytes, and markers of early and late lymphocyte activation.

  • The relationship between IL-8 levels and cognitive impairment in patients with polymorbidity

    by L.V. Ryabova, K.S. Savchuk, E.P. Shishmintseva

    In recent years, there has been an increase in polymorbidity in therapeutic practice. The clinical symptoms of polymorbidity are quite diverse and nonspecific. Depletion of the neuroimmunoendocrine systems is one of the factors contributing to the development of polymorbidity. The aim of the study was to evaluate the relationship between interleukin-8 levels and cognitive impairment in patients with polymorbidity. Patients complaining of memory impairment were selected after the second stage of an in-depth medical examination of citizens who had recovered from the novel coronavirus infection COVID-19. Inclusion criteria were the presence of three chronic diseases simultaneously in one patient (post-COVID syndrome, type 2 diabetes mellitus, hypertension); signed informed voluntary consent. Exclusion criteria: a history of acute cerebrovascular and coronary circulatory disorders; lymphoproliferative diseases; malignant neoplasms. The study included 22 patients with polymorbidity, including 14 women and 8 men, with an average age of 62.09±8.96 years. Using the multiplex assessment method, the concentration of interleukin-8 in the blood serum was determined to be 8.35 (5.50; 9.33) pg/ml. An analysis of correlation relationships was performed to assess the influence of interleukin-8 concentration on the clinical picture of polymorbidity. Based on the analysis results, a positive correlation was established between the concentration of interleukin-8 and complaints of memory impairment (r=0.663; p=0.002). According to the literature, an increase in the concentration of interleukin-8 was observed in neurodegenerative diseases such as Alzheimer’s disease and vascular dementia. It was shown that cytokines can modulate the function of neurons and glial cells, contributing to neurodegeneration. The data obtained in our study support the role of interleukin-8 in cognitive-related neuroinflammation in polymorbidity.

  • Open Access

    Dynamics of the content of shaped blood elements and phagocytic activity of neutrophils in patients with acute coronary syndrome in the postcovoid state and without it, depending on the number of CD8+T-lymphocytes

    by E. A. Safronova, L. V. Ryabova, A. V. Zurochka, M. A. Dobrynina, E. A. Praskurnichy

    Objective: To evaluate hematological parameters and neutrophil phagocytic activity in patients with acute coronary syndrome (ACS) with and without post-COVID syndrome (PCS), according to CD8 + T-lymphocyte counts. Materials and methods: Sixty-five men with ACS were examined. Complete blood counts, neutrophil phagocytic activity, and CD8 + T-lymphocyte counts were assessed at baseline and on day 28. Results: The greatest leukocytosis was observed in patients whose CD8 + T-lymphocyte counts were within the reference range; leukocyte counts in this group decreased significantly by day 28 (p+ counts, regardless of PCS status. The phagocytic number of neutrophils also increased significantly over time in the low-CD8 group (p+ counts within the reference range. Conclusions: After coronary stent implantation, patients with ACS and either low or normal CD8 + T-lymphocyte counts showed by day 28 a reduction in leukocytes, granulocytes and band neutrophils and an increase in lymphocytes, consistent with a beneficial effect of stenting. The phagocytic number and phagocytic intensity of neutrophils increased significantly in patients with reduced CD8 + counts (both with and without PCS), whereas NBT-induced activity and index decreased (p+ counts within the reference range.

  • Open Access

    Disturbances in Carbohydrate Metabolism as a Predictor of Decreased Quality of Life in Patients with Post-COVID Syndrome

    by Saint Petersburg Pasteur Institute, K.S. Savchuk, Russian Federation Saint Petersburg, Russian Federation City Clinical Polyclinic No.8; Chelyabinsk, A.S. Simbirtsev, L.V. Ryabova

    Aim. To characterize the quality of life of patients with post-COVID syndrome depending on the presence of newly identified carbohydrate metabolism disorders (CMD) in the post-COVID period. Design. Cross-sectional study. Materials and methods. A total of 132 people with post-COVID syndrome were examined. The patients were divided into two groups: group 1 included 72 people with newly diagnosed impaired glucose tolerance (IGT) (n = 36) and type 2 diabetes mellitus (DM) (n = 36) in the post-COVID period, and group 2 included 60 people without concomitant CMD. The groups were comparable in terms of age and gender. The average age of patients in group 1 was 61.0 [53.3; 66.5] years (with IGT — 58.5 [54.2; 62.5] years, with DM — 63.5 [51.0; 68.3] years), there were 26 men (36.1%), 46 women (63.9%); the average age of group 2 was 56.5 [51.0; 66.0] years, men — 24 (40.0%), women — 36 (60.0%). The duration of the course of post-COVID syndrome at the time of inclusion in the study in patients with IGT was 6.0 [4.8; 6.0] months, with type 2 diabetes — 6.0 [5.0; 6.0] months. The presence of post-COVID syndrome was established on the basis of signs and symptoms that developed during and / or after COVID-19 infection, lasted more than 12 weeks and were not explained by an alternative diagnosis. The diagnosis of CMD (type 2 diabetes and IGT) was established in accordance with the Algorithms for specialized medical care for patients with diabetes mellitus (2021). The quality of life of patients was determined by conducting a questionnaire using the SF-36 questionnaire, containing 8 assessment scales: physical functioning, role physical functioning, vital activity, general health, mental health, social functioning, role emotional functioning, pain intensity, which form two parameters — psychological and physical components of health. The indicators of each scale vary from 0 to 100 points, and a higher result corresponds to a better quality of life of the subject. Patients filled out the questionnaire themselves, the analysis of the results was carried out using a specially developed computer program. Results. The study groups were characterized by polymorbidity, in the 1st group, dyslipidemia (61.1%) and diseases of the urinary system (33.3%) were significantly more common. Patients with CMD had statistically significantly lower quality of life indicators according to the physical and role functioning scales, amounting to 55.00 and 25.00%, respectively. IGT and type 2 diabetes mellitus, first identified in individuals with post-COVID syndrome, had the most significant impact on the assessment of the physical component of health (33.29%), the indicator of the psychological component of health (52.36%) was comparable to that in the group without CMD (54.12%). Conclusion. The combination of post-COVID syndrome and CMD significantly reduces a number of quality of life indicators in this category of patients. One of the significant predictors of deterioration in quality of life in individuals with post-COVID syndrome according to the physical and role functioning scales is CMD identified for the first time in the post-COVID period. Keywords: diabetes mellitus, impaired glucose tolerance, quality of life, SF-36 questionnaire, patients with post-COVID syndrome

  • Open Access

    Genetic basis of metabolic syndrome

    by Liana V. Riabova, Ksenia S. Savchuk

    Metabolic syndrome is a common heterogeneous condition representing a combination of metabolic abnormalities that increase the risk of cardiovascular disease, type 2 diabetes, and other conditions. Over the past decade, studies of the pathogenesis of metabolic syndrome have advanced through the development of molecular genetics, transcriptomics, and sequencing technologies. Numerous studies have demonstrated that the analysis of genetic markers and epigenetic changes associated with metabolic disorders and chronic inflammation is an important area in exploring the pathogenesis and etiology of this condition. The purpose of this review was to describe chromosomal loci and gene polymorphisms associated with metabolic syndrome based on recent Russian and international data published over the last 10 years. Chromosomal loci and gene polymorphisms were assessed in accordance with the main components of metabolic syndrome: insulin resistance, atherogenic dyslipidemia, central obesity, and hypertension. Chromosomal loci specific to patients with manifestations of metabolic syndrome have been identified; however, no single etiologically significant locus has been established to date. The significance of apolipoprotein A5 and E2 gene polymorphisms in the development of metabolic syndrome has been confirmed. The association between FTO gene polymorphism and obesity has been validated. The GCKR gene is associated with elevated triglyceride levels and contributes to the development of obesity and insulin resistance. The BUD13 rs7118999 polymorphism increases the risk of metabolic syndrome. The IL-6 gene polymorphism is associated not only with metabolic syndrome but also with coronary heart disease and type 2 diabetes. The TCF7L2 gene polymorphism is associated with an increased risk of hypertension and low high-density lipoprotein cholesterol levels. The polymorphisms of adiponectin and leptin genes have also been linked to various components of metabolic syndrome. Thus, the findings of studies on gene polymorphisms indicate that most of these genetic variants are involved in lipid metabolism, and a common genetic basis for metabolic syndrome has not yet been established.

  • Impact of comorbid pathology on the cytokine cascade in the population of a large industrial city (using Chelyabinsk as an example)

    by Andrey S. Simbirtsev, Liana V. Ryabova, Kseniya S. Savchuk, Симбирцев Андрей Семенович

    BACKGROUND: The steady increase in the number of patients with comorbid pathology in large industrial cities necessitates the study of the immune response in this category of patients. AIM: To investigate the cytokine profile of residents of a large industrial city (using Chelyabinsk as an example) depending on the presence of comorbid pathology (type 2 diabetes mellitus, obesity, hypertension). MATERIALS AND METHODS: The cross-sectional study included 61 people, including 39 people with type 2 diabetes mellitus and 22 clinically healthy volunteers. The multiplex assessment method was used to evaluate the concentrations of 11 cytokines in the blood serum: GM-CSF, IFN-γ, IL-2, IL-4, IL-5, IL-8, IL-12p70, IL-13, IL-17A, MIP-1β, TNF-α (pg/ml). RESULTS: Determination of the concentration of cytokines in the blood serum of patients with comorbid pathology in Chelyabinsk revealed a number of features, consisting in the predominance of proinflammatory cytokines and chemokines (IFN-γ, TNF-α, IL-8, MIP-1β, IL-12p70, IL-17A) and a shift in the Th1/Th2 balance towards the proinflammatory phenotype Th1. CONCLUSIONS: The obtained results confirm the presence of inflammation in comorbid pathology (type 2 diabetes mellitus, obesity, hypertension) in the population of Chelyabinsk.

  • Open Access

    Dynamic assessment of T-lymphocytes and humoral immunity in patients with acute coronary syndrome, with and without COVID-19, depending on the content of CD3+CD8+T-lymphocytes

    by E. A. Safronova, L. V. Ryabova, A. V. Zurochka, M. A. Dobrynina, E. V. Zadorina

    Objective: to evaluate the dynamics of the T- and B-cell immunity in patients with acute coronary syndrome (ACS) who have and have not had COVID-19, depending on the number of CD3+CD8+T-lymphocytes.Materials and methods: 65 men with ACS who underwent coronary artery stenting were examined. Immunological parameters were studied using flow cytometry, a complete blood count at baseline and 28 days after admission.Results: The maximum troponin level was observed in individuals with ACS who had recovered from COVID-19 and had a normal level of CD3+CD8+T cells. Stent thromboses and deaths occurred only among patients with a history of COVID-19, mainly with reduced CD3+CD8+T- cells, for which indicators of immune status were determined over time. The absolute numbers of T lymphocytes, T helper cells, late activated T lymphocytes, B lymphocytes (CD3-CD19+CD5+), B lymphocytes (CD45+CD3-CD19+) were minimal in individuals with low CD3+CD8+ T lymphocytes who had previously suffered from COVID-19, and significantly increased in their dynamics after 28 days. Natural killer cells significantly increased in dynamics in patients with initially low and normal CD3+CD8+T-lymphocytes who suffered from COVID-19.Conclusions: after stenting of the coronary arteries over time, in people with reduced CD3+CD8+Tlymphocytes and patients with COVID-19, T-lymphocytes (CD45+CD3+CD19-), T-helper cells, CD3+CD8+T-lymphocytes significantly increased, T-NK lymphocytes, NK lymphocytes, late-activated T-lymphocytes, T-regulatory lymphocytes and late-activated T-regulatory cells, B-lymphocytes, immunoglobulin G and complement fragment C3a decreased. T-regulatory lymphocytes and late-activated T-regulatory cells were significantly reduced in patients without prior COVID-19 with baseline low CD3+CD8+T-lymphocytes. In individuals with normal CD3+CD8+T-lymphocytes who recovered from COVID-19, T-lymphocytes (CD45+CD3+CD19-), NK-lymphocytes, and late-activated T-lymphocytes increased over time.


  • The effect of post-covid syndrome on the cytokine cascade in patients with type 2 diabetes mellitus

    by Kseniya S. Savchuk, Andrey S. Simbirtsev, Liana V. Ryabova, Симбирцев Андрей Семенович

    With the increasing prevalence of type 2 diabetes, it is of interest to study the characteristics of the immunological status in this category of patients. According to modern data, in type 2 diabetes, a pro-inflammatory type of immune response is formed with an imbalance between T-helper 1 (Th1), T-helper 2 (Th2), T-helper 17 (Th17) types and T-regulatory cells (Treg). The COVID-19 pandemic makes a certain contribution to changes in the immune response in patients with type 2 diabetes mellitus, since in patients who have had coronavirus infection, significant changes in the composition of circulating immune cells are observed: the proportion of Th17 increases and the number of Tregs decreases. This study is devoted to identifying the features of the cytokine cascade in patients with type 2 diabetes mellitus, depending on the presence of a confirmed history of SARS-CoV-2 infection. The study included 75 patients with type 2 diabetes, in 36 of them the diagnosis was verified in the post-Covid period. The study was conducted at least 6 months after pneumonia caused by SARS-CoV-2 infection. All study participants signed informed consent. The study was approved by the Independent Local Ethics Committee at the State Autonomous Institution of Regional Clinical Hospital “City Clinical Hospital No. 1” of Chelyabinsk, protocol No. 8 dated 04/11/2022, on the basis of which these studies were conducted. Using the multiplex assessment method, the concentrations of 15 cytokines in the blood serum were assessed in patients: GM-CSF, IFNγ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p70), IL-13, IL-17A, MIP-1β, TNFα. The results obtained during the study showed not only a change in the number of cytokines, but also a change in the balance of pro- and anti-inflammatory cytokines, cytokines that regulate forms of development of acquired immunity, in the group of patients with type 2 diabetes in the post-Covid period. In the post-Covid period, in patients with type 2 diabetes mellitus, the concentrations of cytokines secreted by Th1, Th2, Th17 cells, and Tregs sharply decreased. It has been determined that patients with type 2 diabetes mellitus after SARS-CoV-2 infection develop a functionally inferior virus-specific T-cell response, characterized by reduced or suppressed secretion of the cytokines GM-CSF, IFNγ, IL-1β, IL-2, IL -4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p70), IL-13, IL-17A, MIP-1β, TNFα. A weak T-cell response may increase the likelihood of developing pathological processes associated with an inadequate response to viral antigens (including repeated infections with the SARSCoV-2 virus, exacerbation of chronic infections).


  • Open Access

    Alteration in innate immune cues assessed by analyzing peripheral blood immune system in post-covid patients

    by Maria Aleksandrovna Dobrynina, Aleksandr Vladimirovich Zurochka, Mariia Vladimirovna Komelkova, Vladimir Aleksandrovich Zurochka, Evgeny Arkadyevich Praskurnichiy, Liana Valentinovna Ryabova, Alexey Petrovich Sarapultsev

    The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has led to global morbidity and mortality. Some patients fully recover from COVID-19, whereas around 45% subjects suffer from various persistent symptoms (fatigue, cognitive impairment, impaired thermoregulation, skin diseases, etc.) for at least four months after SARS-CoV-2 infection regardless of disease severity. Such persistent post-infection effects are known as long-COVID, post-acute effects of COVID-19, or post-COVID state. SARS-CoV-2 infection is accompanied by damage to the innate immune system. Considering the role of natural killer cells and the activation of the complement system in COVID-19 as well as the regulatory properties related to CD46 and its potential involvement in cell virus entry, we found necessary to study immune system parameters associated with impairment of these innate immune cues on various leukocyte subpopulations in post-COVID patients. We studied 92 immune system parameters, including: pan-leukocyte markers for gated lymphocytes, phenotyping of T cells, T-helper inducers, cytotoxic T-lymphocytes, NK- and TNK-cells, T-regulatory cells/suppressors, B-lymphocytes, including B-memory cells, activated helpers, early activation of lymphocytes, activated T-lymphocytes, and late lymphocyte activation markers. Levels of total IgM, IgG, IgA, specific IgM, IgG to coronavirus COVID-19, C1-inhibitor, C3a, and C5a complement components were measured by enzyme immunoassay using Multiscan FC Thermoscientific enzyme immunoassay analyzer (China) and Vector Best reagent kits (Russia). A complete blood count was conducted to study 25 parameters: leukocyte, erythrocyte, and platelet hematopoietic lineages as well as the quantitative and qualitative composition of hematopoietic lineages. Our study results showed that in some patients, six months after suffering from COVID-19, there was a decrease in the level of NK cells (48%) and CD46+pan-leukocyte marker cells (64.5%). A decrease in NK cell levels was accompanied by increased level of total T- and B-lymphocytes, and altered platelet and erythroid hematopoietic lineages. In patients with reduced CD46 expression on T-lymphocytes, both their total count and NK cell count were significantly reduced. Our data also suggest that CD46 might be potentially involved in development of SARS-CoV-2 infection and the post-COVID state. Thus, in 50–65% of patients who have experienced SARS-CoV-2 infection, damage to the innate immune system persists after six months being accompanied by impaired erythroid and platelet hematopoietic lineages. The data obtained indicate a need for using immunocorrective therapy in such patients.